Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients.

RESULTS In‐vitro tumor cytotoxicity model and T cell model The dimer, trimer, tetramer, and total active‐species concentrations increased with rising ISB 2001 and teclistamab concentrations; however, a decreasing trend was observed for ISB 2001‐BCMA‐CD38 trimer and ISB 2001‐CD4+/CD8+ T cell‐CD38‐BCMA tetramers at 20 nM ( Figure S1B ).

also in 47,180 other papers